Finance

Lists
TORNTPHARM:NSE
Torrent Pharmaceuticals Ltd
4 800,00 INR
-1,92%
(-94,00) 1D
30 სექ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for TORNTPHARM...
Open
4 935,00 INR
High
4 935,00 INR
Low
4 786,00 INR
Mkt. cap
1,63 ტრლ.
Avg. vol.
332,81 ათ.
Volume
398,00 ათ.
Dividend
0,79%
Quarterly dividend
9,50 INR
Ex-dividend date
29 მაი. 2026
P/E ratio
76,68
52-wk high
5 250,00 INR
52-wk low
3 480,60 INR
EPS
62,60 INR
Shares outstanding
170,00 მლნ.
No. of employees
18 ათ.
Open
4 935,00 INR
High
4 935,00 INR
Low
4 786,00 INR
Mkt. cap
1,63 ტრლ.
Avg. vol.
332,81 ათ.
Volume
398,00 ათ.
Dividend
0,79%
Quarterly dividend
9,50 INR
Ex-dividend date
29 მაი. 2026
P/E ratio
76,68
52-wk high
5 250,00 INR
52-wk low
3 480,60 INR
EPS
62,60 INR
Shares outstanding
170,00 მლნ.
No. of employees
18 ათ.
Profile
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics. Wikipedia
About Torrent Pharmaceuticals Ltd
CEO-
Employees18,3 ათ.
Founded1959
Headquartersაჰმადაბადი, გუჯარათი, ინდოეთი
SectorPharmaceutical industry
Websitetorrentpharma.com
Last report
30 ივლ. 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
15,30 INR / 16,20 INR
-5,55%miss
Revenue / Est. (INR)
49,21 მლრდ. / 47,29 მლრდ.
+4,07%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
33,02 მლრდ.
33,03 მლრდ.
41,97 მლრდ.
49,21 მლრდ.
Cost of goods sold
8,00 მლრდ.
7,99 მლრდ.
10,15 მლრდ.
11,63 მლრდ.
Cost of revenue
8,00 მლრდ.
7,99 მლრდ.
10,15 მლრდ.
11,63 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,27 მლრდ.
6,51 მლრდ.
8,48 მლრდ.
8,93 მლრდ.
Operating expense
16,23 მლრდ.
16,22 მლრდ.
23,34 მლრდ.
26,87 მლრდ.
Total operating expenses
24,23 მლრდ.
24,21 მლრდ.
33,49 მლრდ.
38,50 მლრდ.
Operating income
8,79 მლრდ.
8,82 მლრდ.
8,48 მლრდ.
10,71 მლრდ.
Other non operating income
-270,00 მლნ.
-130,00 მლნ.
794,40 მლნ.
-120,00 მლნ.
EBT including unusual items
7,91 მლრდ.
8,14 მლრდ.
5,29 მლრდ.
7,33 მლრდ.
EBT excluding unusual items
8,04 მლრდ.
8,24 მლრდ.
5,47 მლრდ.
7,54 მლრდ.
Income tax expense
2,00 მლრდ.
1,79 მლრდ.
1,65 მლრდ.
1,67 მლრდ.
Effective tax rate
25,28%
21,99%
31,18%
22,78%
Other operating expenses
7,92 მლრდ.
7,65 მლრდ.
9,78 მლრდ.
12,01 მლრდ.
Net income
5,91 მლრდ.
6,35 მლრდ.
3,89 მლრდ.
5,66 მლრდ.
Net profit margin
17,90%
19,22%
9,28%
11,50%
Earnings per share
17,75
19,00
12,85
15,30
Interest and investment income
-
-
384,30 მლნ.
-
Interest expense
-480,00 მლნ.
-450,00 მლნ.
-2,36 მლრდ.
-3,05 მლრდ.
Net interest expenses
-480,00 მლნ.
-450,00 მლნ.
-1,97 მლრდ.
-3,05 მლრდ.
Depreciation and amortization charges
2,04 მლრდ.
2,06 მლრდ.
5,08 მლრდ.
5,93 მლრდ.
EBITDA
10,82 მლრდ.
10,69 მლრდ.
11,12 მლრდ.
13,35 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები